The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | NSCLC: the increasing need for PD-L1 testing
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the questions surrounding PD-L1 testing in non-small cell lung cancer (NSCLC). PD-L1 immunohistochemistry testing is being developed in order to help make informed clinical decisions about prescribing appropriate immunotherapeutic agents. Not all patients respond to PD-1/PD-L1 inhibitor treatment and prior PD-L1 testing should be predictive of this so that patients can be selected for treatment. Moreover, if prescribed incorrectly, it can be damaging to the patient as these drugs are somewhat toxic. Recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
